The USAN Council has approved "pegrizeprument" as the nonproprietary name for Veloxis Pharmaceuticals' lead transplant candidate VEL-101, marking a significant milestone in the drug's development pathway.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.